(Q35169049)

6 August 2017

1 reference

title

Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being (English)

1 reference

6 August 2017

Thomas A Medsger

1

1 reference

6 August 2017

language of work or name

1 reference

1 May 2003

1 reference

Rheumatic Diseases Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

255-73, vi

1 reference

Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Severe restrictive lung disease in systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The cardiovascular manifestations of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Factors predicting development of renal involvement in progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Autoantibody reactive with RNA polymerase III in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Regressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Serial pulmonary function in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Pulmonary involvement in systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Prognostic importance of cardiac arrhythmias in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The management of renal scleroderma: experience with dialysis, nephrectomy and transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

A histologic evaluation of mixed connective tissue disease in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

A simple severity of disease index for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Measurement of systemic lupus erythematosus activity in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Cytokine production and serum levels in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Interleukin-1, Interleukin-2, Interleukin-4, Interleukin-6, Tumor Necrosis Factor α, and Interferon-γ Levels in Sera from Patients With Scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

E-selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis. Role of resident mast cell-derived tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Soluble immunologic products in scleroderma sera

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Activation of the complement system in systemic sclerosis. Relationship to clinical severity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Ultrasonic measurement of skin thickness in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Measurement of functional status, self-assessment, and psychological well-being in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The development and application of indices of health: general methods and a summary of results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Development and validation of a self-administered systemic sclerosis questionnaire (SySQ).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Psychological adjustment to systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Predictors of psychosocial adjustment in systemic sclerosis. The influence of formal education level, functional ability, hardiness, uncertainty, and social support

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Reliability and validity of the Arthritis Hand Function Test in adults with systemic sclerosis (scleroderma).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

Depressive symptoms associated with scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900023-1

7 January 2021

10.1016/S0889-857X(03)00023-1

Identifiers

DOI

1 reference

6 August 2017

1 reference